EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary objective of this study is to describe the percentage of patients with HER2-positive and Triple Negative tumour underwent neoadjuvant treatment in clinical practice during the past 5 years out of total number of patients who underwent neoadjuvant treatment, regardless molecular subtypes. Secondary objectives The secondary objectives which are limited to molecular subtypes of study interest, HER2-positive and Triple Negative tumours, are follow reported: * To perform a descriptive analysis on neoadjuvant treatment choice according to molecular subtype and initial staging; * To perform a descriptive analysis on clinical and tumour pathological characteristics according to molecular subtypes and initial staging; * To perform radiological response descriptive analysis achieved with neoadjuvant therapy according to treatment and instrumental examination type (for example: breast MRI, breast ultrasound or mammography); * To perform a descriptive analysis of surgical procedures for both, the breast and the axilla, according to radiological tumour response, initial staging and molecular subtypes; * To perform a descriptive analysis on therapies performed in adjuvant setting according to neoadjuvant treatment type, initial staging and molecular subtypes; * To describe and to analyse the eligibility criteria evolution in neoadjuvant treatment setting during the last 5 years; * To perform a descriptive analysis on pathological complete response (cPR) according to neoadjuvant treatment, molecular subtypes and initial staging; * To evaluate disease-free survival (DFS) according to pCR and molecular subtypes; * To evaluate overall survival (OS) according to pCR and molecular subtypes.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona histologicznie rak piersi (biopsja piersi lub węzłów chłonnych)
- •Wiek 18 lat lub więcej w momencie diagnozy
- •Nowotwór w zaawansowaniu I, II lub III (bez przerzutów odległych)
- •Znany status markerów ER, PgR, HER-2 i Ki67
- •Leczenie przedoperacyjne chemioterapią w okresie 01.01.2016 - 01.01.2021
✗ Disqualifies
- •Przerzuty odległe w momencie diagnozy lub w ciągu 3 miesięcy od operacji
- •Poprzednie leczenie hormonalne przed operacją
- •Historia wcześniejszego raka piersi lub innego nowotworu w przeszłości
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- March 25, 2025
- Sex
- No restrictions
Locations (29)
IRCCS - Centro di Riferimento Oncologico (C.R.O.) di Aviano
Aviano, Italy
AOU Ospedali Riuniti Torrette di Ancona
Ancona, Italy
A.O.R.N. "San Giuseppe Moscati"
Avellino, Italy
Presidio di Brindisi Di Summa - Perrino
Brindisi, Italy
Humanitas Istituto Clinico Catanese
Catania, Italy
Azienda Ospedaliera Universitaria "San Martino" - Istituto Nazionale per la Ricerca sul Cancro
Genova, Italy
ASST - Azienda Ospedaliera Carlo Poma di Mantova
Mantua, Italy
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
Meldola, Italy
Istituto Europeo di Oncologia
Milan, Italy
ASST - Ospedale Sacco
Milan, Italy
Azienda Ospedaliera Universitaria - P.O. di Modena
Modena, Italy
Azienda Ospedaliera "A. Cardarelli"
Naples, Italy
Istituto Nazionale Tumori di Napoli - IRCCS Istituto Pascale
Naples, Italy
Universita' degli Studi di Napoli Federico II
Naples, Italy
Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
Novara, Italy
Azienda Ospedaliero-Universitaria di Parma
Parma, Italy
Azienda Ospedaliera Regionale San Carlo
Potenza, Italy
Nuovo Ospedale di Prato - S. Stefano
Prato, Italy
Azienda Ospedaliera San Camillo Forlanini
Roma, Italy
AOU Policlinico Umberto I
Roma, Italy
Ospedale Sandro Pertini - ASL Roma 2
Roma, Italy
Fondazione Policlinico A. Gemelli, IRCCS
Roma, Italy
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, Italy
Fondazione Policlinico Universitario A. Gemelli
Roma, Italy
Arcispedale di Santo Spirito in Sassia - Nuovo Regina Margherita
Roma, Italy
Azienda Socio Sanitaria Territoriale ( ASST ) della Valtellina e Alto Lario Presidio di Sondalo
Sondalo, Italy
A.O.U. Città della salute e della scienza - Presidio Molinette
Torino, Italy
APSS - Ospedale Santa Chiara di Trento
Trento, Italy
Ospedale di Belcolle - Viterbo
Viterbo, Italy
Trial contact
Alessandra Fabi, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.